Results 91 to 100 of about 99,136 (277)

Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. [PDF]

open access: yes, 2015
Somatic mutations in the spliceosome gene ZRSR2-located on the X chromosome-are associated with myelodysplastic syndrome (MDS). ZRSR2 is involved in the recognition of 3'-splice site during the early stages of spliceosome assembly; however, its precise ...
Ganser, Arnold   +16 more
core   +2 more sources

Trisomy 14 as the only cytogenetic abnormality in myelodysplastic syndrome

open access: yesОнкогематология
Evaluation of bone marrow cytogenetic abnormalities in myelodysplastic syndrome is of great importance for confirming the clonal disease nature, determining the prognosis and choosing treatment tactics.
M. N. Pautova   +3 more
doaj   +1 more source

ETV6/GOT1 fusion in a case of t(10;12)(q24;p13)-positive myelodysplastic syndrome

open access: yesHaematologica, 2008
The ETV6/GOT1 fusion, resulting from t(10;12) (q24;p13), has been recently described in a myelodysplastic syndrome. We reported a second case of t(10;12)-positive myelodysplastic syndrome in whom fluorescent in situ hybridization confirmed the non-random
Stephanie Struski   +5 more
doaj   +1 more source

Clinical Images: Vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome presenting as aseptic pustular dermatosis: A rare clinical manifestation

open access: yes
Arthritis &Rheumatology, EarlyView.
Peter Chen   +6 more
wiley   +1 more source

Peripheral versus Marrow Lipidomics in Patients with Severe Aplastic Anemia: Potential Indicators for Early Immunosuppressive Treatment Response

open access: yesLipids, EarlyView.
ABSTRACT This study aimed to explore the differences of peripheral blood (PB) and bone marrow serum lipidomic profiles in severe aplastic anemia (SAA) patients and their significance in predicting earlier immunosuppressive therapy (IST) response. A cohort of 11 newly diagnosed SAA patients and 15 healthy controls were enrolled between June 2020 and ...
Zexing Sun   +11 more
wiley   +1 more source

Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma

open access: yesIJU Case Reports
Introduction Enfortumab vedotin is an antibody‐drug conjugate targeting Nectin‐4 for the treatment of advanced urothelial carcinoma in patients previously treated with platinum‐containing chemotherapy and immune checkpoint inhibitors.
Kazuki Yanagida   +5 more
doaj   +1 more source

Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2014
BACKGROUND: At the time of diagnosis, more than 50% of patients with myelodysplastic syndrome have a normal karyotype and are classified as having a favorable prognosis. However, these patients often show very variable clinical outcomes.
Fernando Barroso Duarte   +6 more
doaj   +1 more source

A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms [PDF]

open access: yes, 2011
Background: Alterations in the DNA methylation pattern are a hallmark of leukemias and lymphomas. However, most epigenetic studies in hematologic neoplasms (HNs) have focused either on the analysis of few candidate genes or many genes and few HN entities,
Agirre, Xabier   +34 more
core  

Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation [PDF]

open access: yes, 2017
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for patients with acute myeloid leukemia (AML). However, post-HCT relapse and regimen-related toxicity remain significant barriers to long-term survival.
Al Mumma   +41 more
core   +1 more source

Engineering Dosimetric Excellence In Total Body Irradiation: Tomotherapy‐Driven Protocols for Precision and Reproducibility

open access: yesPrecision Radiation Oncology, EarlyView.
• Objective: Assess helical Tomotherapy‐based TBI for clinical feasibility, dosimetric reproducibility, and in‐vivo accuracy using dual‐orientation simulation and patient‐specific QA. • Methodology: Implementation of ArcCHECK 3D diode array, ionization chamber verification, and in‐vivo dosimetry with OSLDs at 16 anatomical sites to ensure precise dose ...
Sandeep Singh   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy